Episode 26: Deep Margin goes down under! Lachlan MacDowell talks PROs, survivorship and TROG.

We're honoured to welcome back great friend of the show Kevin Harrington who talks us through the ASCO data, his own hobby horses and gives food for thought for ESMO! Will asks more great questions and Ben is there too.

Andrew Schache joins us - our first New Zealander but out second from the Liverpool head and neck unit. Drawing on his extensive experience, Professor Schache also reflects on the evolution of reconstructive surgery, key developments within the field, and the importance of research, education and innovation in improving patient care. Whether you are a medical student, trainee, surgeon, academic or simply interested in how surgical practice continues to develop, this episode offers an engaging and accessible insight into the past, present and future of reconstruction in surgery.

Lockie MacDowell from Princess Alexandra Hospital in Brisbane and the 'Red Journal' talks to us about PROs and his work in helping generate really important evidence around survivorship. We talk sex, side effects, symptoms, communication and mobilising internal resources - something for everyone!

Prof Evans joins us live from sunny Wales to give us the lowdown on TNM 9 and where it sits. This will give Ben and Will something to talk about at parties.

Professor Neil Gross from MD Anderson talks us through his absolutely seminal work in the field of cutaneous SCCs and what this looks like for the head and neck community. Cemiplimab, EMPOWER, C-POST, neaodjuvant strategies - something for all the family.

Professor Terry Jones, Professor of Head and Neck surgery in Liverpool UK talks us throught the PATHOS trial. Pathos is Greek for "suffering," "experience," or "emotion" and he's shares his work on the trial!

Another rockstar joins us for a great episode talking through some of the advances in head and neck de-escalation

We're back with Chris Holsinger for part 2 of the TORS adventure

Alan Ho, Medical oncologist at MSKCC talks us through his work around Ozuriftamab Vedotin (Oz-V) and other ADC approaches. Ben criticises Will's combination approaches.

Nadeem Riaz directs the Precision Radiotherapy Initiative and leads a multidisciplinary research lab at the intersection of the DNA damage response and anti-tumor immunity. He talks us through his important paper examining mechanisms of resistance and some of the pitfalls of academia.